Srpx for treatment of cancer
Patent Number: US20160206693
Executive Summary:
General Description:
Lung cancer is the leading cause of cancer-related death worldwide. Advanced-stage non-small-cell lung cancer (NSCLC) is currently considered an incurable disease. Although newer chemotherapeutic agents, such as bevacizumab, have been introduced, the median overall survival of patients with metastatic NSCLC remains approximately 1 year, and only 3 to 4% of patients with metastatic NSCLC survive 5 years after diagnosis. This invention has a potential to significantly improve the clinical outcome for patients diagnosed with NSCLC and metastatic NSCLC. It is based on the surprising discovery that, although previously believed to be active intracellularly, a secreted form of the Sushi-Repeat-containing Protein, X-linked (SRPX) protein induces senescence and/or apoptosis in lung cancer cells and in other types of cancer. It describes methods of treating tumors cancers using SRPX-related polypeptides delivered to the extracellular surface of tumor cells, or promoting SRPX expression and secretion by the patient’s cells and implanting these cells into or near the tumor.
Future Directions:
Strengths:
Weaknesses:
Patent Status:
Inventor Bio: Michael R. Green
http://www.hhmi.org/scientists/michael-r-green
Executive Summary:
- Invention Type: Therapeutic
- Patent Status: Pending
- Patent Link: https://patents.google.com/patent/US20160206693/
- Research Institute: University of Massachusetts Medical School
- Disease Focus: Cancer
- Basis of Invention: The inventors observed that a secreted form of the Sushi-Repeat-containing Protein, X-linked (SRPX) protein induces senescence and/or apoptosis (programmed cell death) in cancer cells
- How it works: SRPX is delivered to the tumor site by injection or implantation of a the recombinant SRPX protein or cells expression SRPX protein. SRPX promotes senescence and apoptosis of tumor cells
- Lead Challenge Inventor: Michael R. Green
- Inventors: Michael R. Green, Guangping Gao, Manas Kumar Santra, Sanchita Bhatnagar
- Development Stage: Pre-clinical
- Reduced expression of SPRX in cancer cells is validated on samples derived from patients
- The anti-tumor activity of SPRX is demonstrated in cancer cell lines and in vivo in mice
- Novelty:
- SRPX has been previously thought to act only inside the cell where it was expressed, not being secreted and act through the cell surface receptors in trans
- SPRX can be delivered to the tumor as a recombinant protein, peptidomimetic, or by introduction of DNA encoding it in the form of an adenovirus-based expression vector
- SRPX has been previously thought to act only inside the cell where it was expressed, not being secreted and act through the cell surface receptors in trans
- Clinical Applications:
- Treatment of lung cancers, especially non-small-cell lung carcinoma
- Treatment of other common cancers, including a melanoma, carcinoma, breast cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, or papillary thyroid carcinoma
- Treatment of cancers with reduced expression of SRPX
- Treatment of lung cancers, especially non-small-cell lung carcinoma
General Description:
Lung cancer is the leading cause of cancer-related death worldwide. Advanced-stage non-small-cell lung cancer (NSCLC) is currently considered an incurable disease. Although newer chemotherapeutic agents, such as bevacizumab, have been introduced, the median overall survival of patients with metastatic NSCLC remains approximately 1 year, and only 3 to 4% of patients with metastatic NSCLC survive 5 years after diagnosis. This invention has a potential to significantly improve the clinical outcome for patients diagnosed with NSCLC and metastatic NSCLC. It is based on the surprising discovery that, although previously believed to be active intracellularly, a secreted form of the Sushi-Repeat-containing Protein, X-linked (SRPX) protein induces senescence and/or apoptosis in lung cancer cells and in other types of cancer. It describes methods of treating tumors cancers using SRPX-related polypeptides delivered to the extracellular surface of tumor cells, or promoting SRPX expression and secretion by the patient’s cells and implanting these cells into or near the tumor.
Future Directions:
- Pre-clinical studies
- Phase I clinical trials
Strengths:
- A potent agent promoting death of lung cancer cells
- Acts extracellularly, no need to deliver inside each tumor cell
Weaknesses:
- The proposed therapeutic agent is a polypeptide, which usually means high cost of the therapy
- The research results have not been published in peer-reviewed journals yet
Patent Status:
- Filing date: 2016-03-18
- Publication date: 2016-07-21
Inventor Bio: Michael R. Green
http://www.hhmi.org/scientists/michael-r-green